Related Experiment Videos
Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients
James B Wetmore1, Jonathan D Mahnken, Purna Mukhopadhyay
1Department of Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, Kansas City, KS 66160, USA. jwetmore@kumc.edu
Insights
Cardioprotective antihypertensive medication use in dialysis patients varied significantly by state and patient demographics. Geographic factors and clinical uncertainty may influence prescribing patterns for these high-risk individuals.
Area of Science:
- Nephrology
- Cardiology
- Health Services Research
Background:
- Patients on long-term dialysis face high cardiac risks but show suboptimal use of cardioprotective antihypertensives.
- This study investigates factors influencing the prescription of ACE inhibitors/ARBs, beta-blockers, and calcium channel blockers in this population.
Purpose of the Study:
- To explore demographic, clinical, and geographic factors associated with cardioprotective antihypertensive medication use in hypertensive long-term dialysis patients.
- To identify variations in medication prescribing across different states.
Main Methods:
- A national cross-sectional retrospective analysis linked Medicaid prescription claims with US Renal Data System data.
- The study included 48,882 hypertensive long-term dialysis patients dually eligible for Medicaid and Medicare in 2005.
- Multilevel logistic regression models were used to analyze factors associated with medication use.
Main Results:
- Cardioprotective antihypertensive use was linked to younger age, female sex, nonwhite race, intact functional status, and in-center hemodialysis.
- Diabetes increased ACE-inhibitor/ARB odds by 28%, while congestive heart failure showed minimal association with beta-blocker or ACE-inhibitor/ARB use.
- Significant state-by-state variations in prescribing were observed, with over a 2.9-fold difference for ACE inhibitors/ARBs and 3.6-fold for beta-blockers between highest and lowest prescribing states.
Conclusions:
- Marked state-level differences in antihypertensive use among publicly insured dialysis patients suggest potential influences from Medicaid benefits and geographic factors.
- Clinical uncertainty regarding medication utility may contribute to prescribing variations.
- Findings highlight the need for further investigation into optimizing cardioprotective medication use in this vulnerable population.
Background:
Despite their high risk of adverse cardiac outcomes, persons on long-term dialysis therapy have had lower use of antihypertensive medications with cardioprotective properties, such as angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), β-blockers, and calcium channel blockers, than might be expected. We constructed a novel database that permits detailed exploration into the demographic, clinical, and geographic factors associated with the use of these agents in hypertensive long-term dialysis patients.
Study Design:
National cross-sectional retrospective analysis linking Medicaid prescription drug claims with US Renal Data System core data.
Setting & Participants:
48,882 hypertensive long-term dialysis patients who were dually eligible for Medicaid and Medicare services in 2005.
Factors:
Demographics, comorbid conditions, functional status, and state of residence.
Outcomes:
Prevalence of cardioprotective antihypertensive agents in Medicaid pharmacy claims and state-specific observed to expected ORs of medication exposure.
Measurements:
Factors associated with medication use were modeled using multilevel logistic regression models.
Results:
In multivariable analyses, cardioprotective antihypertensive medication exposure was associated significantly with younger age, female sex, nonwhite race, intact functional status, and use of in-center hemodialysis. Diabetes was associated with a statistically significant 28% higher odds of ACE-inhibitor/ARB use, but congestive heart failure was associated with only a 9% increase in the odds of β-blocker use and no increase in ACE-inhibitor/ARB use. There was substantial state-by-state variation in the use of all classes of agents, with a greater than 2.9-fold difference in adjusted-rate ORs between the highest and lowest prescribing states for ACE inhibitors/ARBs and a 3.6-fold difference for β-blockers.
Limitations:
Limited generalizability beyond study population.
Conclusions:
In publicly insured long-term dialysis patients with hypertension, there were marked differences in use rates by state, potentially due in part to differences in Medicaid benefits. However, geographic characteristics also were associated with exposure, suggesting clinical uncertainty about the utility of these medications.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications